<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">JCP</journal-id>
<journal-id journal-id-type="hwp">jclinpharm</journal-id>
<journal-id journal-id-type="nlm-ta">J Clin Pharmacol</journal-id>
<journal-title>The Journal of Clinical Pharmacology</journal-title>
<issn pub-type="ppub">0091-2700</issn>
<issn pub-type="epub">1552-4604</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0091270011398361</article-id>
<article-id pub-id-type="publisher-id">10.1177_0091270011398361</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Pharmacokinetics and Pharmacodynamics</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Reevaluation of Moxifloxacin Pharmacokinetics and Their Direct Effect on the QT Interval</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Grosjean</surname><given-names>Philippe</given-names></name>
<degrees>MS</degrees>
</contrib>
<contrib contrib-type="author">
<name><surname>Urien</surname><given-names>Saïk</given-names></name>
<degrees>MD, PhD</degrees>
</contrib>
</contrib-group>
<aff id="aff1-0091270011398361">Sanofi-Aventis R&amp;D, Chilly-Mazarin, France (Mr Grosjean)</aff>
<aff id="aff2-0091270011398361">CIC-0901 Inserm Necker-Cochin and EA-3620, Paris, France (Dr Urien)</aff>
<aff id="aff3-0091270011398361">Université Paris Descartes, Paris, France (Mr Grosjean, Dr Urien)</aff>
<author-notes>
<corresp id="corresp1-0091270011398361">Philippe Grosjean, Sanofi-Aventis R&amp;D, Clinical and Exploratory Pharmacology, 1, Avenue Pierre Brossolette, 91385 Chilly-Mazarin, France; e-mail: <email>philippe.grosjean@sanofi-aventis.com</email>.</corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>3</month>
<year>2012</year>
</pub-date>
<volume>52</volume>
<issue>3</issue>
<fpage>329</fpage>
<lpage>338</lpage>
<history>
<date date-type="received">
<day>22</day>
<month>10</month>
<year>2010</year>
</date>
<date date-type="accepted">
<day>31</day>
<month>12</month>
<year>2010</year>
</date>
</history>
<permissions>
<copyright-statement>© 2012 American College of Clinical Pharmacology, Inc.</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="society">American College of Clinical Pharmacology, Inc.</copyright-holder>
</permissions>
<abstract>
<p>The objectives of this study were to investigate the population pharmacokinetics of moxifloxacin and their relationship with the observed QT interval as well as the effect of covariates in healthy subjects using nonlinear mixed-effects modeling. A pool of 4 thorough QT studies were used, representing 99 healthy subjects who received moxifloxacin. The data were modeled using Monolix. Moxifloxacin pharmacokinetics were ascribed a 2- compartment open model. The TRANSIT model provided a better description of the delay in absorption than did the LAG model. The most significant covariate was lean body mass (LBM). The population estimates for clearance and central volume of distribution were 10.0 L/h per 60 kg of LBM and 131 L per 60 kg of LBM, respectively. The effect of moxifloxacin on QT was investigated using a direct effect model. The SLOPE model, relating the QT increase as a linear function of concentration, provided a better description of the pharmacodynamic effect than did the Emax model. The unique covariate was gender for both baseline QT and individual heart rate correction factor. The pharmacokinetics of moxifloxacin were satisfactorily described by an open 2-compartmental model with linear elimination. The trigonometric equation with a direct and proportional concentration effect satisfactorily described the effect on QT.</p>
</abstract>
<kwd-group>
<kwd>Moxifloxacin</kwd>
<kwd>QT interval</kwd>
<kwd>pharmacokinetic/pharmacodynamic modeling</kwd>
<kwd>concentration–response</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<p>The International Conference on Harmonization (ICH) guidance for industry, “Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-antiarrhythmic Drugs” (ICH E14, 2005), describes the assessment of drug-induced QT/corrected QT (QTc) interval prolongation of new drugs in clinical development.<sup><xref ref-type="bibr" rid="bibr1-0091270011398361">1</xref></sup> This publication outlines a relatively standardized method for conduct of a “thorough QT/QTc” trial. The current regulatory guidelines suggest using the largest time-matched QTc mean difference between drug and placebo (baseline-adjusted) over the sampling interval. An alternative under investigation is the evaluation of the relationship between drug concentration and QT/QTc effects, the characterization of which is routinely performed during regulatory reviews. The guidelines also encourage exploring the adequacy of the model fit to the assumption of linearity and the impact on quantifying the concentration relationship.<sup><xref ref-type="bibr" rid="bibr2-0091270011398361">2</xref>-<xref ref-type="bibr" rid="bibr4-0091270011398361">4</xref></sup></p>
<p>The most commonly used positive control is the fluoroquinolone antibiotic moxifloxacin; a single oral dose of 400 mg consistently produces QT/QTc interval prolongation around the level of regulatory concern without conferring proarrhythmic risk to study subjects.<sup><xref ref-type="bibr" rid="bibr1-0091270011398361">1</xref>,<xref ref-type="bibr" rid="bibr5-0091270011398361">5</xref></sup></p>
<p>Trial-to-trial variations in the QT/QTc effect of moxifloxacin were observed among studies. The underlying reasons for this variation in moxifloxacin-induced prolongation of the QT/QTc interval have not been widely investigated. Sources of variation should be investigated, and the direct relationship between the QT/QTc effect and the moxifloxacin pharmacokinetic (PK) profile should be assessed.</p>
<p>The objectives of this study were to develop a population PK/pharmacodynamic (PD) model for moxifloxacin in healthy subjects using nonlinear mixed-effects modeling, to examine possible effects of covariates on moxifloxacin PK and the direct relationship with the observed QT interval.</p>
<sec id="section1-0091270011398361" sec-type="methods">
<title>Methods</title>
<p>Four thorough QT studies that collected moxifloxacin PK data, providing a reasonable sample size and rich PK and PD data, were pooled for this assessment.</p>
<p>All studies were conducted according to Good Clinical Practices and local regulations and were approved by a local ethics committee or an independent review board. Written informed consent was obtained from each subject before any study procedure was carried out. Certified healthy subjects aged 18 to 45 years were eligible. All subjects underwent a screening process after which eligibility was assessed by the investigators before randomization.</p>
<p>Among the pooled studies, a total of 99 healthy young male and female subjects received a single oral dose of 400 mg of moxifloxacin. The number of evaluable subjects in each study ranged from 22 to 29. The studies were randomized, double-blind, double-dummy, parallel design. To allow the double dummy, the moxifloxacin tablets were overencapsulated in a size 00 gelatin capsule.</p>
<p>Coincident thorough PK and PD time points were determined based upon the known PK profile of the investigational products under development and therefore vary slightly between the studies (<xref ref-type="table" rid="table1-0091270011398361">Table I</xref>).</p><p>Blood samples were immediately centrifuged to yield plasma. Plasma concentrations of moxifloxacin were measured using liquid chromatography– tandem mass spectrometry. The limit of quantification was 25 ng/mL.</p>
<table-wrap id="table1-0091270011398361" position="float">
<label>Table I</label>
<caption><p>Time Points for Moxifloxacin Pharmacokinetic Sampling and Electrocardiograph Measurements</p></caption>
<graphic alternate-form-of="table1-0091270011398361" xlink:href="10.1177_0091270011398361-table1.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup>
<thead>
<tr>
<th/>
<th align="center" colspan="19">Time After Dose, h</th>
</tr>
<tr>
<th align="left">Study</th>
<th align="center">0.25</th>
<th align="center">0.5</th>
<th align="center">1</th>
<th align="center">1.5</th>
<th align="center">2</th>
<th align="center">2.5</th>
<th align="center">3</th>
<th align="center">3.5</th>
<th align="center">4</th>
<th align="center">4.5</th>
<th align="center">5</th>
<th align="center">6</th>
<th align="center">8</th>
<th align="center">9</th>
<th align="center">10</th>
<th align="center">12</th>
<th align="center">16</th>
<th align="center">23</th>
<th align="center">24</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td/>
<td>X</td>
<td/>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td/>
<td/>
<td>X</td>
<td>X</td>
<td>X</td>
<td/>
</tr>
<tr>
<td>2</td>
<td/>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td/>
<td>X</td>
<td>X</td>
<td>X</td>
<td/>
<td>X</td>
<td>X</td>
<td/>
<td/>
<td>X</td>
</tr>
<tr>
<td>3</td>
<td/>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td/>
<td>X</td>
<td>X</td>
<td>X</td>
<td/>
<td>X</td>
<td>X</td>
<td>X</td>
<td/>
<td>X</td>
</tr>
<tr>
<td>4</td>
<td/>
<td>X</td>
<td>X</td>
<td/>
<td>X</td>
<td/>
<td>X</td>
<td/>
<td>X</td>
<td/>
<td>X</td>
<td>X</td>
<td/>
<td>X</td>
<td/>
<td>X</td>
<td/>
<td/>
<td>X</td>
</tr>
</tbody>
</table>
</table-wrap>
<p>Twelve-lead electrocardiographs (ECGs) were recorded in triplicate at each time point with at least 1 minute between measurements. All measurements were digitized and sent to a centralized reading center for manual reading. The baseline ECG was that measured before dosing. The average of triplicate ECG at each time point was used in the analysis. Among the ECG parameters measured, the mean QT interval and mean heart rate were used in this PKPD analysis for assessment of direct relationship with corresponding moxifloxacin concentrations.<sup><xref ref-type="bibr" rid="bibr6-0091270011398361">6</xref></sup></p>
<sec id="section2-0091270011398361">
<title>PKPD Modeling</title>
<sec id="section3-0091270011398361">
<title>Pharmacokinetics</title>
<p>A 2-compartment open model with linear absorption and elimination and lag time (LAG model) was first fitted to moxifloxacin data. Then, transit compartments were added (TRANSIT model) to improve the curve-fitting during the absorption phase.<sup><xref ref-type="bibr" rid="bibr7-0091270011398361">7</xref></sup> The possible PK models were</p>
<p>
<disp-formula id="disp-formula1-0091270011398361">
<mml:math display="block" id="math1-0091270011398361">
<mml:mtable columnalign="left">
<mml:mtr>
<mml:mtd>
<mml:mtext>dG</mml:mtext>
<mml:mo stretchy="false">/</mml:mo>
<mml:mtext>dt</mml:mtext>
<mml:mo>=</mml:mo>
<mml:mo>−</mml:mo>
<mml:msub>
<mml:mtext>k</mml:mtext>
<mml:mrow>
<mml:mtext>TR</mml:mtext>
</mml:mrow>
</mml:msub>
<mml:mo>*</mml:mo>
<mml:mtext>G</mml:mtext>
</mml:mtd>
</mml:mtr>
<mml:mtr>
<mml:mtd>
<mml:msub>
<mml:mtext>dTR</mml:mtext>
<mml:mn>1</mml:mn>
</mml:msub>
<mml:mo stretchy="false">/</mml:mo>
<mml:mtext>dt</mml:mtext>
<mml:mo>=</mml:mo>
<mml:msub>
<mml:mtext>k</mml:mtext>
<mml:mrow>
<mml:mtext>TR</mml:mtext>
</mml:mrow>
</mml:msub>
<mml:mo>*</mml:mo>
<mml:mtext>G</mml:mtext>
<mml:mo>−</mml:mo>
<mml:msub>
<mml:mtext>k</mml:mtext>
<mml:mrow>
<mml:mtext>TR</mml:mtext>
</mml:mrow>
</mml:msub>
<mml:mo>*</mml:mo>
<mml:msub>
<mml:mtext>TR</mml:mtext>
<mml:mn>1</mml:mn>
</mml:msub>
</mml:mtd>
</mml:mtr>
<mml:mtr>
<mml:mtd>
<mml:msub>
<mml:mtext>dTR</mml:mtext>
<mml:mn>2</mml:mn>
</mml:msub>
<mml:mo stretchy="false">/</mml:mo>
<mml:mtext>dt</mml:mtext>
<mml:mo>=</mml:mo>
<mml:msub>
<mml:mtext>k</mml:mtext>
<mml:mrow>
<mml:mtext>TR</mml:mtext>
</mml:mrow>
</mml:msub>
<mml:mo>*</mml:mo>
<mml:msub>
<mml:mtext>TR</mml:mtext>
<mml:mn>1</mml:mn>
</mml:msub>
<mml:mo>−</mml:mo>
<mml:msub>
<mml:mtext>k</mml:mtext>
<mml:mrow>
<mml:mtext>TR</mml:mtext>
</mml:mrow>
</mml:msub>
<mml:mo>*</mml:mo>
<mml:msub>
<mml:mtext>TR</mml:mtext>
<mml:mn>2</mml:mn>
</mml:msub>
</mml:mtd>
</mml:mtr>
<mml:mtr>
<mml:mtd>
<mml:msub>
<mml:mtext>dTR</mml:mtext>
<mml:mtext>n</mml:mtext>
</mml:msub>
<mml:mo stretchy="false">/</mml:mo>
<mml:mtext>dt</mml:mtext>
<mml:mo>=</mml:mo>
<mml:msub>
<mml:mtext>k</mml:mtext>
<mml:mrow>
<mml:mtext>TR</mml:mtext>
</mml:mrow>
</mml:msub>
<mml:mo>*</mml:mo>
<mml:msub>
<mml:mtext>TR</mml:mtext>
<mml:mrow>
<mml:mtext>n</mml:mtext>
<mml:mo>−</mml:mo>
<mml:mn>1</mml:mn>
</mml:mrow>
</mml:msub>
<mml:mo>−</mml:mo>
<mml:msub>
<mml:mtext>k</mml:mtext>
<mml:mrow>
<mml:mtext>TR</mml:mtext>
</mml:mrow>
</mml:msub>
<mml:mo>*</mml:mo>
<mml:msub>
<mml:mtext>TR</mml:mtext>
<mml:mtext>n</mml:mtext>
</mml:msub>
</mml:mtd>
</mml:mtr>
<mml:mtr>
<mml:mtd>
<mml:msub>
<mml:mtext>dA</mml:mtext>
<mml:mn>1</mml:mn>
</mml:msub>
<mml:mo stretchy="false">/</mml:mo>
<mml:mtext>dt</mml:mtext>
<mml:mo>=</mml:mo>
<mml:mtext>ka</mml:mtext>
<mml:mo>*</mml:mo>
<mml:msub>
<mml:mtext>TR</mml:mtext>
<mml:mtext>n</mml:mtext>
</mml:msub>
<mml:mo>−</mml:mo>
<mml:msub>
<mml:mtext>k</mml:mtext>
<mml:mrow>
<mml:mn>10</mml:mn>
</mml:mrow>
</mml:msub>
<mml:mo>*</mml:mo>
<mml:msub>
<mml:mtext>A</mml:mtext>
<mml:mn>1</mml:mn>
</mml:msub>
<mml:mo>−</mml:mo>
<mml:msub>
<mml:mtext>k</mml:mtext>
<mml:mrow>
<mml:mn>12</mml:mn>
</mml:mrow>
</mml:msub>
<mml:mo>*</mml:mo>
<mml:msub>
<mml:mtext>A</mml:mtext>
<mml:mn>1</mml:mn>
</mml:msub>
<mml:mo>−</mml:mo>
<mml:msub>
<mml:mtext>k</mml:mtext>
<mml:mrow>
<mml:mn>21</mml:mn>
</mml:mrow>
</mml:msub>
<mml:mo>*</mml:mo>
<mml:msub>
<mml:mtext>A</mml:mtext>
<mml:mn>2</mml:mn>
</mml:msub>
</mml:mtd>
</mml:mtr>
<mml:mtr>
<mml:mtd>
<mml:msub>
<mml:mtext>dA</mml:mtext>
<mml:mn>2</mml:mn>
</mml:msub>
<mml:mo stretchy="false">/</mml:mo>
<mml:mtext>dt</mml:mtext>
<mml:mo>=</mml:mo>
<mml:msub>
<mml:mtext>k</mml:mtext>
<mml:mrow>
<mml:mn>12</mml:mn>
</mml:mrow>
</mml:msub>
<mml:mo>*</mml:mo>
<mml:msub>
<mml:mtext>A</mml:mtext>
<mml:mn>1</mml:mn>
</mml:msub>
<mml:mo>−</mml:mo>
<mml:msub>
<mml:mtext>k</mml:mtext>
<mml:mrow>
<mml:mn>21</mml:mn>
</mml:mrow>
</mml:msub>
<mml:mo>*</mml:mo>
<mml:msub>
<mml:mtext>A</mml:mtext>
<mml:mn>2</mml:mn>
</mml:msub>
</mml:mtd>
</mml:mtr>
</mml:mtable>
</mml:math>
<graphic alternate-form-of="disp-formula1-0091270011398361" xlink:href="10.1177_0091270011398361-eq1.tif"/>
</disp-formula>
</p>
<p>where G, TR, A<sub>1</sub>, and A<sub>2</sub> stand for the gut, transit, central, and peripheral compartments, respectively, and k<sub>TR</sub>, ka, k<sub>10</sub>, k<sub>12</sub>, and k<sub>21</sub> are the transfer rate constants between compartments (k<sub>10</sub> = CL/Vc, k<sub>12</sub> = Q/Vc, k<sub>21</sub> = Q/Vp). The number, n, of transit compartments was defined as</p>
<p>
<disp-formula id="disp-formula2-0091270011398361">
<mml:math display="block" id="math2-0091270011398361">
<mml:mtext>n</mml:mtext>
<mml:mo>=</mml:mo>
<mml:mtext>Mtt</mml:mtext>
<mml:mo>*</mml:mo>
<mml:msub>
<mml:mtext>k</mml:mtext>
<mml:mrow>
<mml:mtext>TR</mml:mtext>
</mml:mrow>
</mml:msub>
<mml:mo>,</mml:mo>
</mml:math>
<graphic alternate-form-of="disp-formula2-0091270011398361" xlink:href="10.1177_0091270011398361-eq2.tif"/>
</disp-formula>
</p>
<p>where the mean transit time, Mtt, is the average time the drug remains in the transit compartments prior to absorption. The transit model is easily implemented in Monolix using the reserved key words MTT1 and KTR1 in the MLXTRAN coding; the number of transit compartments is deduced from Mtt and k<sub>TR</sub>.</p>
</sec>
<sec id="section4-0091270011398361">
<title>Pharmacodynamics</title>
<p>The QT interval was related to heart rate, clock time, and moxifloxacin concentration (C) according to<sup><xref ref-type="bibr" rid="bibr8-0091270011398361">8</xref></sup></p>
<p>
<disp-formula id="disp-formula3-0091270011398361">
<mml:math display="block" id="math3-0091270011398361">
<mml:mtext>QT</mml:mtext>
<mml:mo>=</mml:mo>
<mml:msub>
<mml:mtext>QT</mml:mtext>
<mml:mn>0</mml:mn>
</mml:msub>
<mml:mo>*</mml:mo>
<mml:msup>
<mml:mtext>RR</mml:mtext>
<mml:mi>α</mml:mi>
</mml:msup>
<mml:mo>+</mml:mo>
<mml:mtext>A</mml:mtext>
<mml:mo>*</mml:mo>
<mml:mi>cos</mml:mi>
<mml:mo stretchy="false">[</mml:mo>
<mml:mn>2</mml:mn>
<mml:mi>π</mml:mi>
<mml:mo stretchy="false">/</mml:mo>
<mml:mn>24</mml:mn>
<mml:mo>*</mml:mo>
<mml:mo stretchy="false">(</mml:mo>
<mml:mtext>t</mml:mtext>
<mml:mo>−</mml:mo>
<mml:mi>ϕ</mml:mi>
<mml:mo stretchy="false">)</mml:mo>
<mml:mo stretchy="false">]</mml:mo>
<mml:mo>+</mml:mo>
<mml:mtext>f</mml:mtext>
<mml:mo stretchy="false">(</mml:mo>
<mml:mtext>C</mml:mtext>
<mml:mo stretchy="false">)</mml:mo>
</mml:math>
<graphic alternate-form-of="disp-formula3-0091270011398361" xlink:href="10.1177_0091270011398361-eq3.tif"/>
</disp-formula>
</p>
<p>where QT<sub>0</sub> is the triplicate mean predose (baseline) QT interval (intercept), RR is the interval between successive R waves (related to heart rate), α is the individual heart rate correction factor, A is the amplitude of circadian rhythm, φ is phase, t is clock time, and f(C) is drug concentration effect. Two drug effect relationships were investigated:</p>
<p>
<disp-formula id="disp-formula4-0091270011398361">
<mml:math display="block" id="math4-0091270011398361">
<mml:mtext>f</mml:mtext>
<mml:mo stretchy="false">(</mml:mo>
<mml:mtext>C</mml:mtext>
<mml:mo stretchy="false">)</mml:mo>
<mml:mo>=</mml:mo>
<mml:mtext>Emax</mml:mtext>
<mml:mo>*</mml:mo>
<mml:mtext>C</mml:mtext>
<mml:mo stretchy="false">/</mml:mo>
<mml:mo stretchy="false">(</mml:mo>
<mml:mtext>C</mml:mtext>
<mml:mo>+</mml:mo>
<mml:msub>
<mml:mtext>C</mml:mtext>
<mml:mrow>
<mml:mn>50</mml:mn>
</mml:mrow>
</mml:msub>
<mml:mo stretchy="false">)</mml:mo>
</mml:math>
<graphic alternate-form-of="disp-formula4-0091270011398361" xlink:href="10.1177_0091270011398361-eq4.tif"/>
</disp-formula>
</p>
<p>and</p>
<p>
<disp-formula id="disp-formula5-0091270011398361">
<mml:math display="block" id="math5-0091270011398361">
<mml:mtext>f</mml:mtext>
<mml:mo stretchy="false">(</mml:mo>
<mml:mtext>C</mml:mtext>
<mml:mo stretchy="false">)</mml:mo>
<mml:mo>=</mml:mo>
<mml:mtext>slope</mml:mtext>
<mml:mo>*</mml:mo>
<mml:mtext>C</mml:mtext>
<mml:mo>,</mml:mo>
</mml:math>
<graphic alternate-form-of="disp-formula5-0091270011398361" xlink:href="10.1177_0091270011398361-eq5.tif"/>
</disp-formula>
</p>
<p>where C denotes the predicted concentration.</p>
</sec>
<sec id="section5-0091270011398361">
<title>Data analysis</title>
<p>Data were analyzed using the nonlinear mixed-effect modeling software program Monolix version 3.1S R2<sup><xref ref-type="bibr" rid="bibr9-0091270011398361">9</xref></sup> (<ext-link ext-link-type="uri" xlink:href="http://wfn.software.monolix.org">http://wfn.software.monolix.org</ext-link>). The data were analyzed sequentially; the PK estimates were fixed for the PD analysis. Parameters were estimated by computing the maximum likelihood estimator of the parameters without any approximation of the model (no linearization) using the stochastic approximation expectation maximization algorithm combined with a Markov chain Monte Carlo procedure. A combined, proportional plus constant error model was used to describe the residual variability (ϵ<sub>PROP</sub> and ϵ<sub>ADD</sub>), and the between-subject variabilities (BSVs or η) were ascribed to an exponential error model. Parameter shrinkage was calculated as [1 – sd(η)/ω], where sd(η) and ω are the standard deviation of individual η parameters and the population model estimate of the BSV, respectively. The likelihood ratio test including the log-likelihood, the Akaike information criterion (AIC), and the Bayesian information criterion (BIC) was used to test different hypotheses regarding the final model, covariate effect on PK parameter(s), residual variability model (proportional vs proportional plus additive error model), and structure of the variance–covariance matrix for the BSV parameters. Diagnostic graphics and other statistics were obtained using the R program.<sup><xref ref-type="bibr" rid="bibr10-0091270011398361">10</xref></sup> From the final model, 400 simulations were performed and the predicted data were compared with the observed data using the visual predictive check (VPC) method. Briefly, the 5th, 50th, and 95th percentiles at each time from both the simulated and observed data were overlaid on the observed data using the R program. A visual inspection was performed to ensure centering of the observed data around the model-predicted median and to ensure that the proportion of observations from the model-predicted 5th and 95th percentile curves was not significantly different from 10%.</p>
</sec>
</sec>
</sec>
<sec id="section6-0091270011398361" sec-type="results">
<title>Results</title>
<sec id="section7-0091270011398361">
<title>Population Characteristics</title>
<p>From the 99 healthy subjects investigated, 1301 moxifloxacin plasma concentrations were available for analysis with a mean of 13.2 time points per subject (range, 10-15). Fifty-five (4.2%) concentrations were reported below the limit of quantification and were considered as left-censored data in the modeling process. There were 1405 ECGs available for analysis with a mean of 14.2 time points per subject (range, 11-16).</p>
<p>The subject characteristics at entry into the studies are summarized in <xref ref-type="table" rid="table2-0091270011398361">Table II</xref>. There were 60 males and 39 females, of whom 78 were Caucasian, 9 were black, 3 were Asian, and 9 were multiracial. All subjects were within the reference ranges established for a healthy population by each investigational site for laboratory, vital signs, and ECG data.</p>
<table-wrap id="table2-0091270011398361" position="float">
<label>Table II</label>
<caption><p>Subject Characteristics (N = 99)</p></caption>
<graphic alternate-form-of="table2-0091270011398361" xlink:href="10.1177_0091270011398361-table2.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th align="left">Parameter</th>
<th align="center">Mean</th>
<th align="center">Median</th>
<th align="center">Range</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, y</td>
<td>27.4</td>
<td>25.0</td>
<td>18-46</td>
</tr>
<tr>
<td>Height, cm</td>
<td>173.3</td>
<td>172.0</td>
<td>156-196</td>
</tr>
<tr>
<td>Body weight, kg</td>
<td>70.2</td>
<td>70.4</td>
<td>48.0-102.3</td>
</tr>
<tr>
<td>Lean body mass, kg</td>
<td>53.9</td>
<td>54.0</td>
<td>38.3-72.5</td>
</tr>
<tr>
<td>Ideal body weight, kg</td>
<td>66.7</td>
<td>66.5</td>
<td>48.6-88.7</td>
</tr>
<tr>
<td>Body mass index, kg/m<sup>2</sup></td>
<td>23.3</td>
<td>23.4</td>
<td>17.7-30.6</td>
</tr>
<tr>
<td>Serum creatinine, µM</td>
<td>77.32</td>
<td>79.56</td>
<td>53.0-103.1</td>
</tr>
<tr>
<td>Serum sodium, mM</td>
<td>139.34</td>
<td>139.00</td>
<td>134.00-145.00</td>
</tr>
<tr>
<td>Serum potassium, mM</td>
<td>4.07</td>
<td>4.10</td>
<td>3.20-5.50</td>
</tr>
<tr>
<td>Serum calcium, mM</td>
<td>2.34</td>
<td>2.33</td>
<td>2.13-2.68</td>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
<sec id="section8-0091270011398361">
<title>Population Pharmacokinetic Modeling</title>
<p>A 2-compartment open model with a delay in absorption and elimination was used to fit the data. The TRANSIT model provided a better description of the absorption process than the LAG model with a decrease of 185 in BIC (see <xref ref-type="table" rid="table3-0091270011398361">Table III</xref>). The parameters of the model were then Mtt, k<sub>TR</sub>, ka, the elimination and diffusional clearances CL/F and Q/F, and the volume of central and peripheral compartments Vc/F and Vp/F, where F is the unknown bioavailability. BSV was estimated for all structural parameters but Vp. Residual variability was described by a combined error model. At this step, CL was 8.85 L/h (3% relative standard error) and the corresponding BSV was 0.221 (8% relative standard error).</p>
<table-wrap id="table3-0091270011398361" position="float">
<label>Table III</label>
<caption><p>Pharmacokinetic Model Building</p></caption>
<graphic alternate-form-of="table3-0091270011398361" xlink:href="10.1177_0091270011398361-table3.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="left"/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th align="left">Model</th>
<th align="center">Details</th>
<th align="center">AIC/BIC</th>
</tr>
</thead>
<tbody>
<tr>
<td>Classic 2-compartment</td>
<td>ka, CL, Vc, Q, Vp<break/>η<sub>ka</sub>, η<sub>Vp</sub> fixed to 0</td>
<td>2274/2302</td>
</tr>
<tr>
<td>Classic 2-compartment with absorption LAG time</td>
<td>Lag, ka, CL, Vc, Q, Vp</td>
<td>604/640</td>
</tr>
<tr>
<td>2-compartment with TRANSIT compartments prior to absorption: TRANSIT</td>
<td>ka, CL, Vc, Q, Vp plus Mtt, Ktr<break/>η<sub>Vp</sub> fixed to 0<break/>η<sup>2</sup>(CL + Vc + Q + Vp) = 1.100</td>
<td>416/455</td>
</tr>
<tr>
<td>TRANSIT, effect of ideal body weight</td>
<td>CL, Q = (IBW/70)<sup>0.75</sup>
<break/>Vc, Vp = (IBW/70)<sup>1</sup>
<break/>η<sup>2</sup>(CL + Vc + Q + Vp) = 0.488</td>
<td>335/374</td>
</tr>
<tr>
<td>TRANSIT, effect of body weight</td>
<td>CL, Q = (BW/70)<sup>0.75</sup><break/>Vc, Vp = (BW/70)<sup>1</sup><break/>η<sup>2</sup>(CL + Vc + Q + Vp) = 0.506</td>
<td>316/355</td>
</tr>
<tr>
<td>TRANSIT, effect of lean body mass</td>
<td>CL, Q = (LBM/60)<sup>0.75</sup><break/>Vc, Vp = (LBM/60)<sup>1</sup><break/>η<sup>2</sup>(CL + Vc + Q + Vp) = 0.319</td>
<td>304/343</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0091270011398361">
<p>AIC, Akaike information criterion; BIC, Bayesian information criterion; BW, body weight in kg; IBW, ideal body weight in kg; LBM, lean body mass in kg; η, between-subject variability; η<sup>2</sup>(CL + Vc + Q + Vp), sum of between-subject variances (η<sup>2</sup>s) for the clearance and volume parameters. For all models, the residual variability was described as a combined error model, constant + proportional components.</p></fn>
</table-wrap-foot>
</table-wrap>
<p>The main covariate effects were body size effects, and lean body mass (LBM)<sup><xref ref-type="bibr" rid="bibr11-0091270011398361">11</xref></sup> was found to be the best body size descriptor for clearance and volume parameters. <xref ref-type="table" rid="table3-0091270011398361">Table III</xref> summarizes the model-building steps for the body size effects. The PK parameters were allometrically normalized for LBM to a 60-kg individual as follows:</p>
<p>
<disp-formula id="disp-formula6-0091270011398361">
<mml:math display="block" id="math6-0091270011398361">
<mml:msub>
<mml:mtext>P</mml:mtext>
<mml:mtext>i</mml:mtext>
</mml:msub>
<mml:mo>=</mml:mo>
<mml:msub>
<mml:mtext>P</mml:mtext>
<mml:mrow>
<mml:mtext>TYPICAL</mml:mtext>
</mml:mrow>
</mml:msub>
<mml:mo>×</mml:mo>
<mml:mo stretchy="false">(</mml:mo>
<mml:msub>
<mml:mtext>LBM</mml:mtext>
<mml:mtext>i</mml:mtext>
</mml:msub>
<mml:mo stretchy="false">/</mml:mo>
<mml:mn>60</mml:mn>
<mml:msup>
<mml:mo stretchy="false">)</mml:mo>
<mml:mrow>
<mml:mtext>PWR</mml:mtext>
</mml:mrow>
</mml:msup>
<mml:mo>,</mml:mo>
</mml:math>
<graphic alternate-form-of="disp-formula6-0091270011398361" xlink:href="10.1177_0091270011398361-eq6.tif"/>
</disp-formula>
</p>
<p>where <italic>i</italic> denotes the <italic>i</italic><sup>th</sup> individual. The power (PWR) exponents were set to ¾ and 1 for the clearance and volume terms, respectively. This significantly decreased the BSV estimate (BSV of CL, Vc, and Q decreased from 0.23 to 0.21, from 0.23 to 0.15, and from 0.99 to 0.50, respectively) and improved the predictive performance of the model with a decrease of 112 in BIC (<xref ref-type="fig" rid="fig1-0091270011398361">Figure 1</xref>).</p>
<fig id="fig1-0091270011398361" position="float">
<label>Figure 1.</label>
<caption><p>Observed moxifloxacin concentrations (DV) versus model predictions (Pop_mean) for the transit model with or without lean body mass (LBM) effect. Left panel, covariate-free model; right panel, model including the effect of LBM on clearance and volume terms on an allometric basis (correlation 0.738 and 0.775, bias −0.01 and −0.03, precision 0.66 and 0.62, for left and right panels, respectively).</p></caption>
<graphic xlink:href="10.1177_0091270011398361-fig1.tif"/>
</fig>
<p><xref ref-type="table" rid="table4-0091270011398361">Table IV</xref> shows the final population PK estimates. Most of the parameters were well estimated with low relative standard errors and were within the range of previously reported data.<sup><xref ref-type="bibr" rid="bibr5-0091270011398361">5</xref>,<xref ref-type="bibr" rid="bibr12-0091270011398361">12</xref></sup> The empirical Bayesian estimate shrinkages were generally low, with values above 20% only for ka and Q.</p>
<table-wrap id="table4-0091270011398361" position="float">
<label>Table IV</label>
<caption><p>Parameter Estimates of the Final Moxifloxacin Population Model in 99 Healthy Subjects: Parameters Normalized After a 60-kg Subject LBM According to Allometric Scaling</p></caption>
<graphic alternate-form-of="table4-0091270011398361" xlink:href="10.1177_0091270011398361-table4.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th align="left">Parameter</th>
<th align="center">Covariate Effect</th>
<th align="center">Estimate (%rse)</th>
<th align="center">BSV (%rse) [Shrinkage]</th>
</tr>
</thead>
<tbody>
<tr>
<td>CL, L/h per 60 kg LBM</td>
<td>(LBM/60)<sup>¾</sup></td>
<td>10.0 (3)</td>
<td>0.213 (8) [0.04]</td>
</tr>
<tr>
<td>Vc, L per 60 kg LBM</td>
<td>(LBM/60)<sup>1</sup></td>
<td>131 (2)</td>
<td>0.148 (9) [0.10]</td>
</tr>
<tr>
<td>Q, L/h per 60 kg LBM</td>
<td>(LBM/60)<sup>¾</sup></td>
<td>4.91 (11)</td>
<td>0.502 (23) [0.45]</td>
</tr>
<tr>
<td>Vp, L per 60 kg LBM</td>
<td>(LBM/60)<sup>1</sup></td>
<td>44.2 (18)</td>
<td>0 (fixed) NA</td>
</tr>
<tr>
<td>k<sub>TR</sub>, h<sup>−1</sup></td>
<td>None</td>
<td>13.5 (20)</td>
<td>1.54 (10) [0.17]</td>
</tr>
<tr>
<td>Mtt, h</td>
<td>None</td>
<td>0.827 (8)</td>
<td>0.709 (8) [0.16]</td>
</tr>
<tr>
<td>ka, h<sup>−1</sup></td>
<td>None</td>
<td>4.35 (20)</td>
<td>1.41 (11) [0.23]</td>
</tr>
<tr>
<td>Residual variability, proportional</td>
<td>NA</td>
<td>0.069 (6)</td>
<td>NA</td>
</tr>
<tr>
<td>Residual variability, constant, mg/L</td>
<td align="center">NA</td>
<td>0.037 (16)</td>
<td align="center">NA</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn2-0091270011398361">
<p>BSV, between-subject variability (η); CL, elimination clearance; ka, time rate constant of absorption; k<sub>TR</sub>, time rate constant of transit; LBM, lean body mass; Mtt, mean transit time; NA, not applicable; Q, intercompartmental clearance; Vc, central volume of distribution; Vp, peripheral volume of distribution; %rse, percentage relative standard error. Clearances and volumes are apparent parameters, clearance/F and V/F, where F is the unknown bioavailability.</p></fn>
</table-wrap-foot>
</table-wrap>
<p>The results of the VPC are depicted in <xref ref-type="fig" rid="fig2-0091270011398361">Figure 2</xref>. The observed concentrations were centered about the model-predicted median, and the proportion of observations from the model-predicted 5th and 95th percentile curves was not significantly different from 10%. Moreover, the corresponding percentiles of observed concentrations were close to the predicted ones.</p>
<fig id="fig2-0091270011398361" position="float">
<label>Figure 2.</label>
<caption><p>Visual predictive check for the final moxifloxacin population model. Circles indicate observed data and asterisks indicate censored data. The solid lines denote the 5th, median, and 95th percentiles from bottom to top of 400 Monte Carlo simulated predictions. The dashed lines stand for the 5th, median, and 95th percentiles of the observed concentrations. The bottom and top lines include the 90% confidence interval.</p></caption>
<graphic xlink:href="10.1177_0091270011398361-fig2.tif"/>
</fig>
</sec>
<sec id="section9-0091270011398361">
<title>Pharmacodynamic Modeling</title>
<p>The effect of moxifloxacin on the QT interval was investigated using direct concentration–QT tendency analysis.</p>
<p>A linear relationship between concentration and effect best fitted the data. The SLOPE model provided a better description of the PD effect than the sigmoid Emax model (see <xref ref-type="table" rid="table5-0091270011398361">Table V</xref>). The parameters of the model were then QT<sub>0</sub>, baseline QT interval (intercept); α, individual heart rate correction factor; A, amplitude of circadian rhythm; and φ, phase. BSVs were estimated for all structural parameters. No covariance terms were identified between the parameters. Residual variability was described by a constant error model.</p>
<table-wrap id="table5-0091270011398361" position="float">
<label>Table V</label>
<caption><p>Pharmacodynamic Model Building</p></caption>
<graphic alternate-form-of="table5-0091270011398361" xlink:href="10.1177_0091270011398361-table5.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="left"/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th align="left">Model</th>
<th align="center">Details</th>
<th align="center">AIC/BIC</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sigmoid relationship (Emax)</td>
<td>QT<sub>0</sub>, α, A, φ, EC<sub>50</sub>, Emax</td>
<td>75 906/75 939</td>
</tr>
<tr>
<td>Linear relationship (SLOPE)</td>
<td>QT<sub>0</sub>, α, A, φ, slope<break/>η<sup>2</sup>(QT<sub>0</sub>, α, A, φ, slope) = 2.9</td>
<td>12 810/12 843</td>
</tr>
<tr>
<td>SLOPE, effect of gender</td>
<td>Gender effect : QT<sub>0</sub>(Male), QT<sub>0</sub>(Female)<break/>Gender effect : α(Male), α(Female)<break/>A, φ, slope<break/>η<sup>2</sup>(QT<sub>0</sub>, α, A, φ, slope) = 2.7</td>
<td>12 766/12 805</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn3-0091270011398361">
<p>AIC, Akaike information criterion; BIC, Bayesian information criterion; η, between-subject variability; %rse, % relative standard error.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>The main covariate effect was gender<sup><xref ref-type="bibr" rid="bibr13-0091270011398361">13</xref>,<xref ref-type="bibr" rid="bibr14-0091270011398361">14</xref></sup> for baseline QT interval and individual heart rate correction factor. This significantly decreased the BSV estimates for QT<sub>0</sub> and α from 0.050 to 0.044 and from 0.247 to 0.140, respectively. <xref ref-type="table" rid="table6-0091270011398361">Table VI</xref> summarizes the results for this final model and <xref ref-type="fig" rid="fig3-0091270011398361">Figure 3</xref> depicts model curve fittings for some representative individuals. Most of the parameters were well estimated with low relative standard errors. The empirical Bayesian estimate shrinkages were generally high except for QT<sub>0</sub>.</p>
<table-wrap id="table6-0091270011398361" position="float">
<label>Table VI</label>
<caption><p>Pharmacodynamic Parameter Estimates of the Final Population Model</p></caption>
<graphic alternate-form-of="table6-0091270011398361" xlink:href="10.1177_0091270011398361-table6.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th align="left">Parameter</th>
<th align="center">Covariate Effect</th>
<th align="center">Estimate (%rse)</th>
<th align="center">BSV (%rse) [Shrinkage]</th>
</tr>
</thead>
<tbody>
<tr>
<td>QT<sub>0</sub>, ms</td>
<td>Male<break/>Female</td>
<td>380 (1)<break/>400 (1)</td>
<td>0.0441 (7) [0.02]</td>
</tr>
<tr>
<td>α</td>
<td>Male<break/>Female</td>
<td>0.254 (4)<break/>0.366 (4)</td>
<td>0.14 (26) [0.49]</td>
</tr>
<tr>
<td>A, ms</td>
<td>NA</td>
<td>2.17 (15)</td>
<td>0.842 (17) [0.36]</td>
</tr>
<tr>
<td>φ, h</td>
<td>NA</td>
<td>17.2 (19)</td>
<td>1.26 (13) [0.45]</td>
</tr>
<tr>
<td>Slope, ms/concentration</td>
<td>NA</td>
<td>1.23 (17)</td>
<td>0.657 (32) [0.51]</td>
</tr>
<tr>
<td>Residual variability, constant</td>
<td>NA</td>
<td>6.8 (2)</td>
<td align="center">NA</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn4-0091270011398361">
<p>α, individual heart rate correction factor; A, amplitude of circadian rhythm; BSV, between-subject variability; φ, phase; NA, not applicable; QT<sub>0</sub>, baseline QT interval (intercept); %rse, percentage relative standard error; slope, linear pharmacodynamic relationship.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<fig id="fig3-0091270011398361" position="float">
<label>Figure 3.</label>
<caption><p>Effect of moxifloxacin on the QT interval: individual curve fitting (circles, observations; solid lines, mean population predictions; dashed lines, individual predictions).</p></caption>
<graphic xlink:href="10.1177_0091270011398361-fig3.tif"/>
</fig>
<p>The VPCs for females and males are depicted in <xref ref-type="fig" rid="fig4-0091270011398361">Figure 4</xref>. For both, the observed QT intervals were centered around the model-predicted median, and the proportion of observations from the model- predicted 5th and 95th percentile curves was not significantly different from 10%. Moreover, the corresponding percentiles of observed QT intervals were close to the predicted ones.</p>
<fig id="fig4-0091270011398361" position="float">
<label>Figure 4.</label>
<caption><p>Visual predictive check for the effect of moxifloxacin on QT interval. Circles indicate observed data. The solid lines denote the 5th, median, and 95th percentiles from bottom to top of 400 Monte Carlo simulated predictions. The dashed lines stand for the 5th, median, and 95th percentiles of the observed concentrations. The bottom and top lines include the 90% confidence interval.</p></caption>
<graphic xlink:href="10.1177_0091270011398361-fig4.tif"/>
</fig>
</sec>
<sec id="section10-0091270011398361">
<title>Limited Sampling Strategy</title>
<p>PFIM (version 3.2.1) optimizes statistical designs in the context of population pharmacokinetics (ie, the group structure, the number of samples per subject, and the sampling times) for a given total number of samples.<sup><xref ref-type="bibr" rid="bibr15-0091270011398361">15</xref></sup> The aim was to decrease the number of PK and PD time points. This was performed using 60 subjects, which is now the recommended subject number in each arm of a parallel-design thorough QT study. With the following 9 sampling times, 0.66, 1, 1.5, 2, 2.75, 3.5, 5.5, 12, and 24 hours, the estimated relative standard errors for the PK parameters were in the range 3% to 49%. The CL, Vc, k<sub>TR</sub>, Mtt, and ka parameters, which contribute most to the peak definition (including the absorption and rapid distribution phases), had particularly accurate relative standard errors: 7.5%, 3.0%, 23%, 10%, and 31%, respectively. The observation time points for the QT interval should minimize the percentage relative standard error of the “slope” parameter, since the difference in QT is directly proportional to the moxifloxacin concentration via this parameter. The following 9 observation times for QT, 0.66, 1, 1.25, 1.5, 2, 2.25, 3.25, 6, and 16 hours, provided a relative standard error of 33% for the estimation of the slope parameter. Deleting the 2- and 2.25-hour time points resulted in a small increase in the relative standard error to 42%. <xref ref-type="fig" rid="fig5-0091270011398361">Figure 5</xref> depicts the time points for these reduced PK and PD designs.</p>
<fig id="fig5-0091270011398361" position="float">
<label>Figure 5.</label>
<caption><p>Moxifloxacin concentration and effect on QT interval versus time for the mean population parameter values used in PK and PD modeling of moxifloxacin using PFIM 3.0. Top panel depicts the 9-time-point reduced PK design. Middle and bottom panels depict the reduced PD designs, with 9 and 7 time points, respectively.</p></caption>
<graphic xlink:href="10.1177_0091270011398361-fig5.tif"/>
</fig>
</sec>
</sec>
<sec id="section11-0091270011398361" sec-type="discussion">
<title>Discussion</title>
<p>The pharmacokinetics of plasma moxifloxacin in healthy subjects were satisfactorily described by an open 2-compartmental model with linear elimination. The VPC showed that this population model was accurate in describing both pharmacokinetics and variability. The use of transit compartments for the absorption process dramatically improved the curve-fitting during the absorption phase.<sup><xref ref-type="bibr" rid="bibr7-0091270011398361">7</xref></sup> A total of approximately 11 transit compartments (n = Mtt * k<sub>TR</sub>) were used to describe the absorption process. The need for this number of transit compartments may be attributable, in part, to the overencapsulation of moxifloxacin tablets used to meet the double-dummy methodology constraints. The moxifloxacin CL estimate, 10.0 L/h per 60 kg of LBM, was close to previously reported estimates in adult healthy subjects, range 10.8 to 19.3 L/h,<sup><xref ref-type="bibr" rid="bibr12-0091270011398361">12</xref></sup> supporting the LBM allometric scaling of volumes and clearances parameters. The central and peripheral volumes of distribution, 131 and 44 L per 60 kg of LBM, are within the range of previously reported data.<sup><xref ref-type="bibr" rid="bibr5-0091270011398361">5</xref>,<xref ref-type="bibr" rid="bibr6-0091270011398361">6</xref></sup> No effects of gender or age were found significant in terms of pharmacokinetics, as expected from this rather homogenous population.</p>
<p>The moxifloxacin effect on QT was satisfactorily described by the trigonometric equation with a direct and proportional concentration effect. The VPC showed that this population model was accurate in describing both the phenomenon and the variability. As expected, gender was a significant covariate in our PD model. In comparison to males, adult females have been shown to exhibit longer baseline QT/QTc intervals and a greater propensity to develop torsades de pointes upon exposure to drugs that prolong the QT/QTc interval.<sup><xref ref-type="bibr" rid="bibr14-0091270011398361">14</xref></sup> Effects of electrolytes (sodium, potassium, chloride) were assessed as they are known to influence cardiac action potential. Normal electrolyte concentrations were ensured in the selected healthy population, and consequently these covariates showed no significant effect on our model. The effect of race was evaluated as a covariate; it was not found to significantly influence our model, perhaps because of the small sample size of some categories. Clock time was taken into consideration in the PD model,<sup><xref ref-type="bibr" rid="bibr8-0091270011398361">8</xref></sup> as diurnal variation of the QT/QTc interval is a well-established phenomenon.</p>
<p>A linear concentration–response or log (concentration)–response model has been used traditionally to describe the overall relationship between concentration and QT. This points to the importance of an accurate description of maximal concentrations after oral intake that will correspond to the greatest increase in QT interval. The time to maximum concentration from the PK model was 2.6 hours, meaning that the expected maximum difference in QT interval, for a “mean” individual, should be observed at that time.</p>
<p>Finally, this PKPD model allows us to propose reduced sampling strategies to obtain satisfactory estimates of the parameters. The present design included 16 time points for both PK and PD evaluations. Using this population model, 9 observation times for both pharmacokinetics and pharmacodynamics could provide satisfactory estimates for the main parameters of interest. Because drug pharmacokinetics are generally known before a thorough QT study and the largest QT variation depends on the peak drug concentration, a limited sampling strategy designed to accurately describe the peak drug concentration could be used to investigate maximal QT variations.</p>
</sec>
</body>
<back>
<ack><p>We acknowledge Franck Poitiers, Biostatistics Department of Sanofi-Aventis, for building the pooled study database.</p></ack>
<fn-group>
<fn fn-type="financial-disclosure">
<p>Financial disclosure: Philippe Grosjean is an employee of Sanofi-Aventis and owns stocks. Saïk Urien does not own stock and has not received honoraria, research funding, or other remuneration.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-0091270011398361">
<label>1.</label>
<citation citation-type="confproc">
<conf-name>International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use</conf-name>. <article-title>The Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs (ICH E14)</article-title>. <publisher-loc>Rockville, Md:</publisher-loc> <publisher-name>US Department of Health and Human Services Food and Drug Administration</publisher-name>. <year>2005</year>.</citation>
</ref>
<ref id="bibr2-0091270011398361">
<label>2.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Garnett</surname><given-names>C</given-names></name>
<name><surname>Beasley</surname><given-names>N</given-names></name>
<name><surname>Bhattaram</surname><given-names>VA</given-names></name>
<etal/>
</person-group>. <article-title>Concentration-QT relationships play a key role in the evaluation of proarrhythmic risk during regulatory review</article-title>. <source>J Clin Pharmacol</source>. <year>2008</year>;<volume>48</volume>:<fpage>13</fpage>-<lpage>18</lpage>.</citation>
</ref>
<ref id="bibr3-0091270011398361">
<label>3.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Russell</surname><given-names>T</given-names></name>
<name><surname>Riley</surname><given-names>SP</given-names></name>
<name><surname>Cook</surname><given-names>JA</given-names></name>
<name><surname>Richard</surname><given-names>L</given-names></name>
<name><surname>Lalonde</surname><given-names>RL</given-names></name>
</person-group>. <article-title>A perspective on the use of concentration-QT modeling in drug development</article-title>. <source>J Clin Pharmacol</source>. <year>2008</year>;<volume>48</volume>:<fpage>9</fpage>-<lpage>12</lpage>.</citation>
</ref>
<ref id="bibr4-0091270011398361">
<label>4.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bloomfield</surname><given-names>D</given-names></name>
<name><surname>Krishna</surname><given-names>R</given-names></name>
</person-group>. <article-title>Commentary on the clinical relevance of concentration/QTc relationships for new drug candidates</article-title>. <source>J Clin Pharmacol</source>. <year>2008</year>;<volume>48</volume>:<fpage>6</fpage>-<lpage>8</lpage>.</citation>
</ref>
<ref id="bibr5-0091270011398361">
<label>5.</label>
<citation citation-type="book">
<collab>Avelox (moxifloxacin) package insert</collab>. <publisher-loc>West Haven, Conn</publisher-loc>: <publisher-name>Bayer Pharmaceuticals</publisher-name>; <year>2003</year>.</citation>
</ref>
<ref id="bibr6-0091270011398361">
<label>6.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mason</surname><given-names>JW</given-names></name>
<name><surname>Florian</surname><given-names>JA</given-names></name>
<name><surname>Garnett</surname><given-names>CE</given-names></name>
<etal/>
</person-group>. <article-title>Pharmacokinetics and pharmacodynamics of three moxifloxacin dosage forms: implications for blinding in active-controlled cardiac repolarization studies</article-title>. <source>J Clin Pharmacol</source>. <year>2010</year>;<volume>50</volume>:<fpage>1249</fpage>-<lpage>1259</lpage>.</citation>
</ref>
<ref id="bibr7-0091270011398361">
<label>7.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Savic</surname><given-names>RA</given-names></name>
<name><surname>Jonker</surname><given-names>DM</given-names></name>
<name><surname>Kerbusch</surname><given-names>T</given-names></name>
<name><surname>Karlsson</surname><given-names>MO</given-names></name>
</person-group>. <article-title>Implementation of a transit compartment model for describing drug absorption in pharmacokinetic studies</article-title>. <source>J Pharmacokinet Pharmacodyn</source>. <year>2007</year>;<volume>34</volume>:<fpage>711</fpage>-<lpage>726</lpage>.</citation>
</ref>
<ref id="bibr8-0091270011398361">
<label>8.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Piotrovsky</surname><given-names>V</given-names></name>
</person-group>. <article-title>Pharmacokinetic-pharmacodynamic modeling in the data analysis and interpretation of drug-induced QT/QTc prolongation</article-title>. <source>AAPS J</source>. <year>2005</year>;<volume>7</volume>:<fpage>E609</fpage>-<lpage>E624</lpage>.</citation>
</ref>
<ref id="bibr9-0091270011398361">
<label>9.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kuhn</surname><given-names>E</given-names></name>
<name><surname>Lavielle</surname><given-names>M</given-names></name>
</person-group>. <article-title>Maximum likelihood estimation in nonlinear mixed effects models</article-title>. <source>Comput Stat Data Anal</source>. <year>2005</year>;<volume>49</volume>:<fpage>1020</fpage>-<lpage>1030</lpage>.</citation>
</ref>
<ref id="bibr10-0091270011398361">
<label>10.</label>
<citation citation-type="book">
<collab>R Development Core Team</collab>. <source>R (2009): A Language and Environment for Statistical Computing</source>. <publisher-loc>Vienna, Austria</publisher-loc>: <publisher-name>R Foundation for Statistical Computing</publisher-name>; <year>2009</year>.</citation>
</ref>
<ref id="bibr11-0091270011398361">
<label>11.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Green</surname><given-names>B</given-names></name>
<name><surname>Duffull</surname><given-names>SB</given-names></name>
</person-group>. <article-title>What is the best size descriptor to use for pharmacokinetic studies in the obese?</article-title> <source>Br J Clin Pharmacol</source>. <year>2004</year>;<volume>58</volume>:<issue>2</issue>:<fpage>119</fpage>-<lpage>133</lpage>.</citation>
</ref>
<ref id="bibr12-0091270011398361">
<label>12.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Moise</surname><given-names>PA</given-names></name>
</person-group>. <article-title>Pharmacokinetics and metabolism of moxifloxacin</article-title>. <source>Drugs of Today</source>. <year>2000</year>;<volume>36</volume>:<fpage>229</fpage>-<lpage>244</lpage>.</citation>
</ref>
<ref id="bibr13-0091270011398361">
<label>13.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sullivan</surname><given-names>TJ</given-names></name>
<name><surname>Lettieri</surname><given-names>TJ</given-names></name>
<name><surname>Liu</surname><given-names>P</given-names></name>
<name><surname>Heller</surname><given-names>A</given-names></name>
</person-group>. <article-title>The influence of age and gender on the pharmacokinetics of moxifloxacin</article-title>. <source>Clin Pharmacokinet</source>. <year>2001</year>;<volume>40</volume>(<issue>suppl 1</issue>):<fpage>1</fpage>-<lpage>18</lpage>.</citation>
</ref>
<ref id="bibr14-0091270011398361">
<label>14.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Drici</surname><given-names>MD</given-names></name>
</person-group>. <article-title>Influence of gender on drug-acquired long QT syndrome</article-title>. <source>Eur Heart J Suppl</source>. <year>2001</year>;<volume>3</volume>(<issue>suppl K</issue>):<fpage>K41</fpage>-<lpage>K47</lpage>.</citation>
</ref>
<ref id="bibr15-0091270011398361">
<label>15.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bazzoli</surname><given-names>C</given-names></name>
<name><surname>Retout</surname><given-names>S</given-names></name>
<name><surname>Mentré</surname><given-names>F</given-names></name>
</person-group>. <article-title>Design evaluation and optimisation in multiple response nonlinear mixed effect models: PFIM 3.0</article-title>. <source>Comput Methods Programs Biomed</source>. <year>2010</year>;<volume>98</volume>:<fpage>55</fpage>-<lpage>65</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>